Feasibility and safety of repeated transarterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma

Tomohiro Matsumoto, Hitoshi Ichikawa, Jin Imai, Toshihiko Hayashi, Kosuke Tomita, Takahiko Mine, Seiichiro Kojima, Norihito Watanabe, Terumitsu Hasebe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: To retrospectively evaluate the feasibility and safety of repeated transarterial chemoembolization (TACE) three or more times using miriplatin-lipiodol (MLPD) suspension (repeated M-LPD TACE) for hepatocellular carcinoma (HCC). Patients and Methods: Sixteen patients who underwent repeated M-LPD TACE were examined. Total dose of miriplatin, lipiodol and porous gelatin sponge particles and adverse events of the first and last M-LPD TACE were evaluated. Results: The mean±standard deviation (SD) of the total number of M-LPD TACE per patient was 3.7±1.1. The mean±SD dose of total miriplatin, lipiodol and porous gelatin sponge particles per patient was 303±103 mg, 21±7.3 ml and 84±57 mg, respectively. There were no significant differences in any adverse events between the first and last M-LPD TACE. Conclusion: Repeated M-LPD TACE for HCC is feasible and safe in selected patients.

Original languageEnglish
Pages (from-to)3183-3187
Number of pages5
JournalAnticancer research
Volume37
Issue number6
DOIs
Publication statusPublished - 2017 Jun

Keywords

  • Hepatocellular carcinoma
  • Miriplatin
  • Transarterial chemoembolization

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Feasibility and safety of repeated transarterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this